|
GENERIC
|
Tafluprost ophthalmic solution 0.0015% (PF)
|
|
SIZE
|
Single use containers | 30 or 90 pack
|
|
INDICATIONS
|
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
|
|
MICROBIOLOGY
|
prostaglandin | prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
|
|
CONTRAINDICATIONS & WARNINGS
|
Increase in pigmentation of the iris and periorbital tissues, increase in length of eyelashes, intraocular inflammation, macular edema. Contact lenses should be removed 15 minutes prior to instillation
|
|
PEDIATRIC USE
|
Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use
|
|
PREGNANCY
|
Pregnancy category C | There are no adequate and well-controlled studies in pregnant woman. Although animal reproduction studies are not always predictive of human response, ZIOPTAN® should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.
|
|
NOTE
|
Zioptan is preservative-free
|
